Screening for 21-hydroxylase–deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study

Objective: To prospectively establish the specificity, sensitivity, and positive predictive value (PPV) of a basal 17-hydroxyprogesterone (17-HP) level for the screening of 21-hydroxylase–deficient nonclassic adrenal hyperplasia (NCAH) among hyperandrogenic women. Design: Prospective observational t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Fertility and sterility 1999-11, Vol.72 (5), p.915-925
Hauptverfasser: Azziz, Ricardo, Hincapie, Luis A, Knochenhauer, Eric S, Dewailly, Didier, Fox, Liesl, Boots, Larry R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 925
container_issue 5
container_start_page 915
container_title Fertility and sterility
container_volume 72
creator Azziz, Ricardo
Hincapie, Luis A
Knochenhauer, Eric S
Dewailly, Didier
Fox, Liesl
Boots, Larry R
description Objective: To prospectively establish the specificity, sensitivity, and positive predictive value (PPV) of a basal 17-hydroxyprogesterone (17-HP) level for the screening of 21-hydroxylase–deficient nonclassic adrenal hyperplasia (NCAH) among hyperandrogenic women. Design: Prospective observational trial. Setting: Tertiary care academic medical centers. Patient(s): Eight healthy controls, 20 patients with NCAH, and 284 consecutively seen patients with hyperandrogenism. Intervention(s): All controls and patients with NCAH, and select patients with hyperandrogenism, underwent acute ACTH (1-24) stimulation. Main Outcome Measure(s): Specificity was determined by measuring 17-HP every other day during one menstrual cycle in 8 healthy women with normal ovulation (107 samples). Sensitivity was determined by measuring 17-HP between 7 and 9 a.m. and 3 and 5 p.m. on the same day in 20 patients with genetically confirmed NCAH. The PPV was determined by prospectively measuring 17-HP in 284 consecutively seen hyperandrogenic women at their initial evaluation. The diagnosis of NCAH was established by a stimulated 17-HP level of >10 ng/mL. Result(s): Among controls, 17-HP levels of 4 ng/mL had sensitivities of 100%, 90%, and 90%, respectively, for the detection of the disorder when obtained in the morning, and sensitivities of 95%, 90%, and 85%, respectively, when obtained in the afternoon. Among the 284 consecutively seen hyperandrogenic women, the PPVs of the first and second 17-HP levels were 7.3% and 19% for a cutoff level of >2 ng/mL, 13% and 43% for a cutoff level of >3 ng/mL, and 33% and 40% for a cutoff level of >4 ng/mL, respectively. Conclusion(s): A basal 17-HP level is a useful screening tool for NCAH. A cutoff level of 4 ng/mL has maximum specificity and PPV, with little loss in sensitivity if testing is performed in the morning and during the follicular phase. However, a lower cutoff level (e.g., 2 or 3 ng/mL) is preferable if testing is performed at odd hours of the day, as is common in many practices, and maximum sensitivity is desired.
doi_str_mv 10.1016/S0015-0282(99)00383-0
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69268417</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0015028299003830</els_id><sourcerecordid>69268417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-4955b157bade516f8cfe538fe77e519506cb114b1a406b472b8e887d527742233</originalsourceid><addsrcrecordid>eNqFkMtu1TAQhi0EoofCI4C8QAgWgbETX9INQhU3qRKLwtpy7ElrlDjBzinNjnfgDXkSfC4CdqysGX3z-9dHyGMGLxkw-eoSgIkKuObP2_YFQK3rCu6QDRNCVkKK-i7Z_EFOyIOcvwKAZIrfJycMhGRl3JDbS5cQY4hXtJ8S5ay6Xn2abtfBZvz146fHPriAcaFxiq4sc3DU-oTRDvR6nTHNZRksteNUMvYbG0vCVQl19Ps0Yjyjls5pyjO6JdwgzcvWrw_Jvd4OGR8d31Py5d3bz-cfqotP7z-ev7monIB6qZpWiI4J1VmPgsleux5FrXtUqsytAOk6xpqO2QZk1yjeadRaecGVajiv61Py7JBbGnzbYl7MGLLDYbARp202suVSN0wVUBxAV6rmhL2ZUxhtWg0Ds1Nu9srNzqdpW7NXbqDcPTl-sO1G9P9cHRwX4OkRsNnZoS9-XMh_OV63jdYFe33AsNi4CZhM3ol36EMq4oyfwn-a_AbwW5_1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69268417</pqid></control><display><type>article</type><title>Screening for 21-hydroxylase–deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Azziz, Ricardo ; Hincapie, Luis A ; Knochenhauer, Eric S ; Dewailly, Didier ; Fox, Liesl ; Boots, Larry R</creator><creatorcontrib>Azziz, Ricardo ; Hincapie, Luis A ; Knochenhauer, Eric S ; Dewailly, Didier ; Fox, Liesl ; Boots, Larry R</creatorcontrib><description>Objective: To prospectively establish the specificity, sensitivity, and positive predictive value (PPV) of a basal 17-hydroxyprogesterone (17-HP) level for the screening of 21-hydroxylase–deficient nonclassic adrenal hyperplasia (NCAH) among hyperandrogenic women. Design: Prospective observational trial. Setting: Tertiary care academic medical centers. Patient(s): Eight healthy controls, 20 patients with NCAH, and 284 consecutively seen patients with hyperandrogenism. Intervention(s): All controls and patients with NCAH, and select patients with hyperandrogenism, underwent acute ACTH (1-24) stimulation. Main Outcome Measure(s): Specificity was determined by measuring 17-HP every other day during one menstrual cycle in 8 healthy women with normal ovulation (107 samples). Sensitivity was determined by measuring 17-HP between 7 and 9 a.m. and 3 and 5 p.m. on the same day in 20 patients with genetically confirmed NCAH. The PPV was determined by prospectively measuring 17-HP in 284 consecutively seen hyperandrogenic women at their initial evaluation. The diagnosis of NCAH was established by a stimulated 17-HP level of &gt;10 ng/mL. Result(s): Among controls, 17-HP levels of &lt;2, &lt;3, and &lt;4 ng/mL all had a specificity of 100% when obtained in the follicular phase; when obtained in the luteal phase, they had specificities of 53%, 82%, and 82%, respectively. Among patients with NCAH, 17-HP levels of &gt;2, &gt;3, and &gt;4 ng/mL had sensitivities of 100%, 90%, and 90%, respectively, for the detection of the disorder when obtained in the morning, and sensitivities of 95%, 90%, and 85%, respectively, when obtained in the afternoon. Among the 284 consecutively seen hyperandrogenic women, the PPVs of the first and second 17-HP levels were 7.3% and 19% for a cutoff level of &gt;2 ng/mL, 13% and 43% for a cutoff level of &gt;3 ng/mL, and 33% and 40% for a cutoff level of &gt;4 ng/mL, respectively. Conclusion(s): A basal 17-HP level is a useful screening tool for NCAH. A cutoff level of 4 ng/mL has maximum specificity and PPV, with little loss in sensitivity if testing is performed in the morning and during the follicular phase. However, a lower cutoff level (e.g., 2 or 3 ng/mL) is preferable if testing is performed at odd hours of the day, as is common in many practices, and maximum sensitivity is desired.</description><identifier>ISSN: 0015-0282</identifier><identifier>EISSN: 1556-5653</identifier><identifier>DOI: 10.1016/S0015-0282(99)00383-0</identifier><identifier>PMID: 10561000</identifier><identifier>CODEN: FESTAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>17-alpha-Hydroxyprogesterone - metabolism ; 21-hydroxylase ; Adrenal ; Adrenal Glands - enzymology ; adrenal hyperplasia ; Adrenal Hyperplasia, Congenital - enzymology ; Adrenals. Adrenal axis. Renin-angiotensin system (diseases) ; androgens ; Basal Metabolism ; Biological and medical sciences ; Case-Control Studies ; Endocrinopathies ; Female ; hirsutism ; Humans ; Mass Screening - methods ; Medical sciences ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Predictive Value of Tests ; Prospective Studies ; Sensitivity and Specificity</subject><ispartof>Fertility and sterility, 1999-11, Vol.72 (5), p.915-925</ispartof><rights>1999 American Society for Reproductive Medicine</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-4955b157bade516f8cfe538fe77e519506cb114b1a406b472b8e887d527742233</citedby><cites>FETCH-LOGICAL-c503t-4955b157bade516f8cfe538fe77e519506cb114b1a406b472b8e887d527742233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0015-0282(99)00383-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3541,23921,23922,25131,27915,27916,45986</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1239488$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10561000$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Azziz, Ricardo</creatorcontrib><creatorcontrib>Hincapie, Luis A</creatorcontrib><creatorcontrib>Knochenhauer, Eric S</creatorcontrib><creatorcontrib>Dewailly, Didier</creatorcontrib><creatorcontrib>Fox, Liesl</creatorcontrib><creatorcontrib>Boots, Larry R</creatorcontrib><title>Screening for 21-hydroxylase–deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study</title><title>Fertility and sterility</title><addtitle>Fertil Steril</addtitle><description>Objective: To prospectively establish the specificity, sensitivity, and positive predictive value (PPV) of a basal 17-hydroxyprogesterone (17-HP) level for the screening of 21-hydroxylase–deficient nonclassic adrenal hyperplasia (NCAH) among hyperandrogenic women. Design: Prospective observational trial. Setting: Tertiary care academic medical centers. Patient(s): Eight healthy controls, 20 patients with NCAH, and 284 consecutively seen patients with hyperandrogenism. Intervention(s): All controls and patients with NCAH, and select patients with hyperandrogenism, underwent acute ACTH (1-24) stimulation. Main Outcome Measure(s): Specificity was determined by measuring 17-HP every other day during one menstrual cycle in 8 healthy women with normal ovulation (107 samples). Sensitivity was determined by measuring 17-HP between 7 and 9 a.m. and 3 and 5 p.m. on the same day in 20 patients with genetically confirmed NCAH. The PPV was determined by prospectively measuring 17-HP in 284 consecutively seen hyperandrogenic women at their initial evaluation. The diagnosis of NCAH was established by a stimulated 17-HP level of &gt;10 ng/mL. Result(s): Among controls, 17-HP levels of &lt;2, &lt;3, and &lt;4 ng/mL all had a specificity of 100% when obtained in the follicular phase; when obtained in the luteal phase, they had specificities of 53%, 82%, and 82%, respectively. Among patients with NCAH, 17-HP levels of &gt;2, &gt;3, and &gt;4 ng/mL had sensitivities of 100%, 90%, and 90%, respectively, for the detection of the disorder when obtained in the morning, and sensitivities of 95%, 90%, and 85%, respectively, when obtained in the afternoon. Among the 284 consecutively seen hyperandrogenic women, the PPVs of the first and second 17-HP levels were 7.3% and 19% for a cutoff level of &gt;2 ng/mL, 13% and 43% for a cutoff level of &gt;3 ng/mL, and 33% and 40% for a cutoff level of &gt;4 ng/mL, respectively. Conclusion(s): A basal 17-HP level is a useful screening tool for NCAH. A cutoff level of 4 ng/mL has maximum specificity and PPV, with little loss in sensitivity if testing is performed in the morning and during the follicular phase. However, a lower cutoff level (e.g., 2 or 3 ng/mL) is preferable if testing is performed at odd hours of the day, as is common in many practices, and maximum sensitivity is desired.</description><subject>17-alpha-Hydroxyprogesterone - metabolism</subject><subject>21-hydroxylase</subject><subject>Adrenal</subject><subject>Adrenal Glands - enzymology</subject><subject>adrenal hyperplasia</subject><subject>Adrenal Hyperplasia, Congenital - enzymology</subject><subject>Adrenals. Adrenal axis. Renin-angiotensin system (diseases)</subject><subject>androgens</subject><subject>Basal Metabolism</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>hirsutism</subject><subject>Humans</subject><subject>Mass Screening - methods</subject><subject>Medical sciences</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Sensitivity and Specificity</subject><issn>0015-0282</issn><issn>1556-5653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtu1TAQhi0EoofCI4C8QAgWgbETX9INQhU3qRKLwtpy7ElrlDjBzinNjnfgDXkSfC4CdqysGX3z-9dHyGMGLxkw-eoSgIkKuObP2_YFQK3rCu6QDRNCVkKK-i7Z_EFOyIOcvwKAZIrfJycMhGRl3JDbS5cQY4hXtJ8S5ay6Xn2abtfBZvz146fHPriAcaFxiq4sc3DU-oTRDvR6nTHNZRksteNUMvYbG0vCVQl19Ps0Yjyjls5pyjO6JdwgzcvWrw_Jvd4OGR8d31Py5d3bz-cfqotP7z-ev7monIB6qZpWiI4J1VmPgsleux5FrXtUqsytAOk6xpqO2QZk1yjeadRaecGVajiv61Py7JBbGnzbYl7MGLLDYbARp202suVSN0wVUBxAV6rmhL2ZUxhtWg0Ds1Nu9srNzqdpW7NXbqDcPTl-sO1G9P9cHRwX4OkRsNnZoS9-XMh_OV63jdYFe33AsNi4CZhM3ol36EMq4oyfwn-a_AbwW5_1</recordid><startdate>19991101</startdate><enddate>19991101</enddate><creator>Azziz, Ricardo</creator><creator>Hincapie, Luis A</creator><creator>Knochenhauer, Eric S</creator><creator>Dewailly, Didier</creator><creator>Fox, Liesl</creator><creator>Boots, Larry R</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991101</creationdate><title>Screening for 21-hydroxylase–deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study</title><author>Azziz, Ricardo ; Hincapie, Luis A ; Knochenhauer, Eric S ; Dewailly, Didier ; Fox, Liesl ; Boots, Larry R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-4955b157bade516f8cfe538fe77e519506cb114b1a406b472b8e887d527742233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>17-alpha-Hydroxyprogesterone - metabolism</topic><topic>21-hydroxylase</topic><topic>Adrenal</topic><topic>Adrenal Glands - enzymology</topic><topic>adrenal hyperplasia</topic><topic>Adrenal Hyperplasia, Congenital - enzymology</topic><topic>Adrenals. Adrenal axis. Renin-angiotensin system (diseases)</topic><topic>androgens</topic><topic>Basal Metabolism</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>hirsutism</topic><topic>Humans</topic><topic>Mass Screening - methods</topic><topic>Medical sciences</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Azziz, Ricardo</creatorcontrib><creatorcontrib>Hincapie, Luis A</creatorcontrib><creatorcontrib>Knochenhauer, Eric S</creatorcontrib><creatorcontrib>Dewailly, Didier</creatorcontrib><creatorcontrib>Fox, Liesl</creatorcontrib><creatorcontrib>Boots, Larry R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fertility and sterility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Azziz, Ricardo</au><au>Hincapie, Luis A</au><au>Knochenhauer, Eric S</au><au>Dewailly, Didier</au><au>Fox, Liesl</au><au>Boots, Larry R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Screening for 21-hydroxylase–deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study</atitle><jtitle>Fertility and sterility</jtitle><addtitle>Fertil Steril</addtitle><date>1999-11-01</date><risdate>1999</risdate><volume>72</volume><issue>5</issue><spage>915</spage><epage>925</epage><pages>915-925</pages><issn>0015-0282</issn><eissn>1556-5653</eissn><coden>FESTAS</coden><abstract>Objective: To prospectively establish the specificity, sensitivity, and positive predictive value (PPV) of a basal 17-hydroxyprogesterone (17-HP) level for the screening of 21-hydroxylase–deficient nonclassic adrenal hyperplasia (NCAH) among hyperandrogenic women. Design: Prospective observational trial. Setting: Tertiary care academic medical centers. Patient(s): Eight healthy controls, 20 patients with NCAH, and 284 consecutively seen patients with hyperandrogenism. Intervention(s): All controls and patients with NCAH, and select patients with hyperandrogenism, underwent acute ACTH (1-24) stimulation. Main Outcome Measure(s): Specificity was determined by measuring 17-HP every other day during one menstrual cycle in 8 healthy women with normal ovulation (107 samples). Sensitivity was determined by measuring 17-HP between 7 and 9 a.m. and 3 and 5 p.m. on the same day in 20 patients with genetically confirmed NCAH. The PPV was determined by prospectively measuring 17-HP in 284 consecutively seen hyperandrogenic women at their initial evaluation. The diagnosis of NCAH was established by a stimulated 17-HP level of &gt;10 ng/mL. Result(s): Among controls, 17-HP levels of &lt;2, &lt;3, and &lt;4 ng/mL all had a specificity of 100% when obtained in the follicular phase; when obtained in the luteal phase, they had specificities of 53%, 82%, and 82%, respectively. Among patients with NCAH, 17-HP levels of &gt;2, &gt;3, and &gt;4 ng/mL had sensitivities of 100%, 90%, and 90%, respectively, for the detection of the disorder when obtained in the morning, and sensitivities of 95%, 90%, and 85%, respectively, when obtained in the afternoon. Among the 284 consecutively seen hyperandrogenic women, the PPVs of the first and second 17-HP levels were 7.3% and 19% for a cutoff level of &gt;2 ng/mL, 13% and 43% for a cutoff level of &gt;3 ng/mL, and 33% and 40% for a cutoff level of &gt;4 ng/mL, respectively. Conclusion(s): A basal 17-HP level is a useful screening tool for NCAH. A cutoff level of 4 ng/mL has maximum specificity and PPV, with little loss in sensitivity if testing is performed in the morning and during the follicular phase. However, a lower cutoff level (e.g., 2 or 3 ng/mL) is preferable if testing is performed at odd hours of the day, as is common in many practices, and maximum sensitivity is desired.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>10561000</pmid><doi>10.1016/S0015-0282(99)00383-0</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0015-0282
ispartof Fertility and sterility, 1999-11, Vol.72 (5), p.915-925
issn 0015-0282
1556-5653
language eng
recordid cdi_proquest_miscellaneous_69268417
source MEDLINE; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects 17-alpha-Hydroxyprogesterone - metabolism
21-hydroxylase
Adrenal
Adrenal Glands - enzymology
adrenal hyperplasia
Adrenal Hyperplasia, Congenital - enzymology
Adrenals. Adrenal axis. Renin-angiotensin system (diseases)
androgens
Basal Metabolism
Biological and medical sciences
Case-Control Studies
Endocrinopathies
Female
hirsutism
Humans
Mass Screening - methods
Medical sciences
Non tumoral diseases. Target tissue resistance. Benign neoplasms
Predictive Value of Tests
Prospective Studies
Sensitivity and Specificity
title Screening for 21-hydroxylase–deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T19%3A17%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Screening%20for%2021-hydroxylase%E2%80%93deficient%20nonclassic%20adrenal%20hyperplasia%20among%20hyperandrogenic%20women:%20a%20prospective%20study&rft.jtitle=Fertility%20and%20sterility&rft.au=Azziz,%20Ricardo&rft.date=1999-11-01&rft.volume=72&rft.issue=5&rft.spage=915&rft.epage=925&rft.pages=915-925&rft.issn=0015-0282&rft.eissn=1556-5653&rft.coden=FESTAS&rft_id=info:doi/10.1016/S0015-0282(99)00383-0&rft_dat=%3Cproquest_cross%3E69268417%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69268417&rft_id=info:pmid/10561000&rft_els_id=S0015028299003830&rfr_iscdi=true